Innocan Pharma anticipates NYSE American listing around January 7

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced it anticipates listing on NYSE American on or around January 7, 2026, subject to approval of its listing application and continued compliance with exchange rules.

The pharmaceutical technology company, which develops drug delivery platform technologies, is conducting a concurrent securities offering in connection with the anticipated NYSE listing, subject to market conditions and regulatory approval. Additional details regarding the offering will be provided through filings with the Securities and Exchange Commission and SEDAR+.

The company expects its common shares will continue trading on the OTC Markets' OTCQB until market close on or about January 6, 2026. Upon effectiveness of the NYSE American listing, OTCQB trading will terminate. Stockholders do not need to take action prior to the NYSE American listing.

Innocan's common shares will continue trading on the Canadian Securities Exchange under the symbol "INNO."

The company operates in pharmaceuticals and wellness sectors. In pharmaceuticals, Innocan developed a CBD-loaded liposome drug delivery platform for non-opioid pain management. In wellness, the company develops self-care and beauty products through its 60% owned subsidiary, BI Sky Global Ltd.

You May Also Be Interested In

• CalciMedica raises up to $49M in private placement for PH program
• EU approves Merck's Keytruda plus Padcev for bladder cancer
• Hertz cuts guidance, announces notes and stock offerings, shares sink